Research programme - anti-inflammatory therapeutics - QBiotics
Latest Information Update: 14 Apr 2023
At a glance
- Originator QBiotics
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 14 Apr 2023 Research programme - Anti-inflammatories therapeutics - QBiotics is available for licensing as of 14 Apr 2023. https://qbiotics.com/ (Qbiotics pipeline, April 2023)
- 14 Apr 2023 Qbiotics has patents pending for research programme in major jurisdictions (Qbiotics pipeline, April 2023)
- 08 Apr 2023 Preclinical trials in Skin disorders in Australia (unspecified route), prior to April 2023 (Qbiotics pipeline, April 2023)